Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Biopharmaceutical Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global biopharmaceutical market size reached US$ 249.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 440.2 Billion by 2027, exhibiting a growth rate (CAGR) of 10.25% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Biopharmaceuticals are complex drugs extracted from biological sources, such as humans, animals and microorganisms, or synthesized using recombinant deoxyribonucleic acid (DNA) technologies. They comprise sugars, proteins, nucleic acids, living cells, tissues, and a complex combination of differen components. They assist in the manufacturing of vaccines, blood components, body cells and tissues, allergenics, and living cells used in cell therapies, gene therapies and recombinant therapeutic proteins. They also help treat cancer, diabetes, cardiovascular diseases, immune diseases, and other health problems while providing targeted treatment and fewer side effects.

Biopharmaceutical Market Trends:

The growing utilization of biopharmaceuticals as immunosera, hormones, cytokines, enzymes, and monoclonal antibodies currently represents one of the key factors driving the market. Moreover, there is a rise in the demand for monoclonal antibodies to treat rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases across the globe. This, along with the rising prevalence of chronic diseases due to excessive use of tobacco and alcohol, poor nutrition, and lack of physical activities, is propelling the growth of the market. In addition, the increasing employment of cell and gene-based biopharmaceuticals to treat a variety of diseases for which no other drugs or medical devices are available is offering lucrative growth opportunities to industry investors. Besides this, key market players are extensively investing in research and development (R&D) activities to introduce innovative drugs for treating untreatable conditions. This, coupled with the rising awareness among the masses about the benefits of biopharmaceuticals, is positively influencing the market. Apart from this, the increasing geriatric population, along with the burgeoning healthcare industry, is catalyzing the demand for biopharmaceuticals. Additionally, the escalating demand for target therapy to target specific genes and proteins that are involved in the growth and survival of cancer cells is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biopharmaceutical market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on indication and class.

Breakup by Indication:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Disorders
  • Metabolic Disorders
  • Others

Autoimmune diseases are presently dominating the market on account of the growing environmental exposure and changing food habits of individuals.

Breakup by Class:

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Purified Proteins

At present, monoclonal antibodies hold the largest market share due to their rising therapeutic applications and the high specificity to a single epitope leading to low cross-reactivity.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Turkey
  • Asia Pacific
    • Japan
    • China
    • Australia
    • South Korea
    • India
    • Indonesia

Currently, North America represents the largest market for biopharmaceuticals across the globe. It is further segmented into the United States and Canada.

Key Questions Answered in This Report:

  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the impact of COVID-19 on the global biopharmaceutical market?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world’s largest biopharmaceutical markets?
  • Which are the world’s fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world’s largest biopharmaceutical segments?
  • Which are the world’s fastest growing biopharmaceutical segments?
  • Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?

1   Preface
2   Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction
5   Global Biopharmaceutical Market

    5.1 Market Performance and Forecast
        5.1.1 Current Performance (2016-2021)
        5.1.2 Market Forecast (2022-2027)
    5.2 Impact of COVID-19
    5.3 Market by Region
        5.3.1 Current Performance (2016-2021)
        5.3.2 Market Forecast (2022-2027)
    5.4 Market by Indication
        5.4.1 Autoimmune Diseases
        5.4.2 Oncology
        5.4.3 Metabolic Disorders
        5.4.4 Others
     5.5 Market by Class
        5.5.1 Recombinant Proteins
            5.5.1.1 Current Performance (2016-2021)
            5.5.1.2 Market Forecast (2022-2027)
        5.5.2 Monoclonal Antibodies
            5.5.2.1 Current Performance (2016-2021)
            5.5.2.2 Market Forecast (2022-2027)
        5.5.3 Purified Proteins
            5.5.3.1 Current Performance (2016-2021)
            5.5.3.2 Market Forecast (2022-2027)
    5.6 Competitive Landscape
        5.6.1 Top Biopharmaceutical Players
        5.6.2 Top Biopharmaceutical Drugs       
    5.7 Value Chain Analysis
    5.8 Porter’s Five Forces Analysis
        5.8.1 Overview
        5.8.2 Bargaining Power of Buyers
        5.8.3 Bargaining Power of Suppliers
        5.8.4 Degree of Rivalry
        5.8.5 Threat of New Entrants
        5.8.6 Threat of Substitutes
6   North America
    6.1 United States
        6.1.1 Market Performance (2016-2021)
        6.1.2 Market by Class
            6.1.2.1 Recombinant Proteins
            6.1.2.2 Monoclonal Antibodies
            6.1.2.3 Purified Proteins
        6.1.3 Top Players
        6.1.4 Market Forecast (2022-2027)
    6.2 Canada
        6.2.1 Market Performance (2016-2021)
        6.2.2 Market by Class
            6.2.2.1 Recombinant Proteins
            6.2.2.2 Monoclonal Antibodies
            6.2.2.3 Purified Proteins
        6.2.3 Top Players
        6.2.4 Market Forecast (2022-2027)
7   Latin America
    7.1 Mexico
        7.1.1 Market Performance (2016-2021)
        7.1.2 Market by Class
            7.1.2.1 Recombinant Proteins
            7.1.2.2 Monoclonal Antibodies
            7.1.2.3 Purified Proteins
        7.1.3 Top Players
        7.1.4 Market Forecast (2022-2027)
    7.2 Brazil
        7.2.1 Market Performance (2016-2021)
        7.2.2 Market by Class
            7.2.2.1 Recombinant Proteins
            7.2.2.2 Monoclonal Antibodies
            7.2.2.3 Purified Proteins
        7.2.3 Top Players
        7.2.4 Market Forecast (2022-2027)
    7.3 Argentina
        7.3.1 Market Performance (2016-2021)
        7.3.2 Market by Class
            7.3.2.1 Recombinant Proteins
            7.3.2.2 Monoclonal Antibodies
            7.3.2.3 Purified Proteins
        7.3.3 Top Players
        7.3.4 Market Forecast (2022-2027)
8   Europe
    8.1 Germany
        8.1.1 Market Performance (2016-2021)
        8.1.2 Market by Class
            8.1.2.1 Recombinant Proteins
            8.1.2.2 Monoclonal Antibodies
            8.1.2.3 Purified Proteins
        8.1.3 Top Players
        8.1.4 Market Forecast (2022-2027)
    8.2 France
        8.2.1 Market Performance (2016-2021)
        8.2.2 Market by Class
            8.2.2.1 Recombinant Proteins
            8.2.2.2 Monoclonal Antibodies
            8.2.2.3 Purified Proteins
        8.2.3 Top Players
        8.2.4 Market Forecast (2022-2027)
   8.3 Italy
        8.3.1 Market Performance (2016-2021)
        8.3.2 Market by Class
            8.3.2.1 Recombinant Proteins
            8.3.2.2 Monoclonal Antibodies
            8.3.2.3 Purified Proteins
        8.3.3 Top Players
        8.3.4 Market Forecast (2022-2027)
    8.4 Spain
        8.4.1 Market Performance (2016-2021)
        8.4.2 Market by Class
            8.4.2.1 Recombinant Proteins
            8.4.2.2 Monoclonal Antibodies
            8.4.2.3 Purified Proteins
        8.4.3 Top Players
        8.4.4 Market Forecast (2022-2027)
    8.5 United Kingdom
        8.5.1 Market Performance (2016-2021)
        8.5.2 Market by Class
            8.5.2.1 Recombinant Proteins
            8.5.2.2 Monoclonal Antibodies
            8.5.2.3 Purified Proteins
        8.5.3 Top Players
        8.5.4 Market Forecast (2022-2027)
    8.6 Russia
        8.6.1 Market Performance (2016-2021)
        8.6.2 Market by Class
            8.6.2.1 Recombinant Proteins
            8.6.2.2 Monoclonal Antibodies
            8.6.2.3 Purified Proteins
        8.6.3 Top Players
        8.6.4 Market Forecast (2022-2027)
    8.7 Turkey
        8.7.1 Market Performance (2016-2021)
        8.7.2 Market by Class
            8.7.2.1 Recombinant Proteins
            8.7.2.2 Monoclonal Antibodies
            8.7.2.3 Purified Proteins
        8.7.3 Top Players
        8.7.4 Market Forecast (2022-2027)
9   Asia Pacific
    9.1 Japan
        9.1.1 Market Performance (2016-2021)
        9.1.2 Market by Class
            9.1.2.1 Recombinant Proteins
            9.1.2.2 Monoclonal Antibodies
            9.1.2.3 Purified Proteins
        9.1.3 Top Players
        9.1.4 Market Forecast (2022-2027)
    9.2 China
        9.2.1 Market Performance (2016-2021)
        9.2.2 Market by Class
            9.2.2.1 Recombinant Proteins
            9.2.2.2 Monoclonal Antibodies
            9.2.2.3 Purified Proteins
        9.2.3 Top Players
        9.2.4 Market Forecast (2022-2027)
    9.3 Australia
        9.3.1 Market Performance (2016-2021)
        9.3.2 Market by Class
            9.3.2.1 Recombinant Proteins
            9.3.2.2 Monoclonal Antibodies
            9.3.2.3 Purified Proteins
        9.3.3 Top Players
        9.3.4 Market Forecast (2022-2027)
    9.4 South Korea
        9.4.1 Market Performance (2016-2021)
            9.4.1.1 Recombinant Proteins
            9.4.1.2 Monoclonal Antibodies
            9.4.1.3 Purified Proteins
        9.4.2 Top Players
        9.4.3 Market Forecast (2022-2027)
    9.5 India
        9.5.1 Market Performance (2016-2021)
        9.5.2 Market by Class
            9.5.2.1 Recombinant Proteins
            9.5.2.2 Monoclonal Antibodies
            9.5.2.3 Purified Proteins
        9.5.3 Top Players
        9.5.4 Market Forecast (2022-2027)
    9.6 Indonesia
        9.6.1 Market Performance (2016-2021)
        9.6.2 Market by Class
            9.6.2.1 Recombinant Proteins
            9.6.2.2 Monoclonal Antibodies
            9.6.2.3 Purified Proteins
        9.6.3 Top Players
        9.6.4 Market Forecast (2022-2027)
10  SWOT Analysis
    10.1 Overview
    10.2 Strengths
    10.3 Weaknesses
    10.4 Opportunities
    10.5 Threats
11  Competitive Landscape
    11.1    Market Structure
    11.2    Key Players
    11.3    Profiles of Key Players
      11.3.1    AbbVie Inc.
      11.3.2    Amgen Inc
      11.3.3    Biogen Inc.
      11.3.4    Eli Lilly and Company
      11.3.5    F. Hoffmann-La Roche AG
      11.3.6    Johnson & Johnson
      11.3.7    Merck & Co. Inc.
      11.3.8    Novo Nordisk A/S
      11.3.9    Pfizer Inc.
      11.3.10    Sanofi S.A

List of Figures

Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 2: Complexity of Biopharmaceuticals
Figure 3: Sources of Biopharmaceuticals
Figure 4: Global: Biopharmaceutical Market: Value Trends (in Million US$), 2016-2021
Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Million US$), 2022-2027
Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2021
Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2027
Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2021
Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2022-2027
Figure 11: Global: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2022-2027
Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2022-2027
Figure 17: Global: Purified Proteins Market (in Million US$), 2016-2021
Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 2022-2027
Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
Figure 22: Global: Biopharmaceutical Industry: Porter’s Five Forces Analysis
Figure 23: United States: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 25: United States: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 29: United States: Purified Proteins Market (in Million US$), 2016-2021
Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2021
Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2021
Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 49: Mexico: Purified Proteins Market (in ‘000 US$), 2016-2021
Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2021
Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 59: Brazil: Purified Proteins Market (in Million US$), 2016-2021
Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2021
Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 69: Argentina: Purified Proteins Market (in Million US$), 2016-2021
Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 79: Germany: Purified Proteins Market (in Million US$), 2016-2021
Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 84: France: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 86: France: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 90: France: Purified Proteins Market (in Million US$), 2016-2021
Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2021
Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 100: Italy: Purified Proteins Market (in Million US$), 2016-2021
Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 110: Spain: Purified Proteins Market (in Million US$), 2016-2021
Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 115: UK: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 117: UK: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 121: UK: Purified Proteins Market (in Million US$), 2016-2021
Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 132: Russia: Purified Proteins Market: (in Million US$), 2016-2021
Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 142: Turkey: Purified Proteins Market (in Million US$), 2016-2021
Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 152: Japan: Purified Proteins Market (in Million US$), 2016-2021
Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million US$), 2022-2027
Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 156: China: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 158: China: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 162: China: Purified Proteins Market: (in Million US$), 2016-2021
Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 173: Australia: Purified Proteins Market (in Million US$), 2016-2021
Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2021
Figure 183: South Korea: Purified Proteins Market (in Million US$), 2016-2021
Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2021
Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 188: India: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 190: India: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 193: India: Purified Proteins Market (in Million US$), 2016-2021
Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2016-2021
Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2016-2021
Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2016-2021
Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2021
Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2016-2021
Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2021
Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2022-2027
Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2027
Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2019
Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2021 & 2027
Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2021 & 2027
Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2019
Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

Table 1: Global: Biopharmaceutical Market: Definition & Segmentation 
Table 2: Global: Biopharmaceutical Market: SWOT Analysis 
Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2021 & 2027
Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals 
Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs 
Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2016-2021
Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2022-2027
Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2021
Table 9: Mode of Administration of Popular Biotech Drugs


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links